Download this datacard
Overview
Lobbying Costs
50,000€ - 99,999€
Financial year: Jan 2021 - Dec 2021
Lobbyists (Full time equivalent)
0.3 Fte (3)
Lobbyists with EP accreditation
1
High-level Commission meetings
1
Lobbying Costs over the years
-
Info
Irish Pharmaceutical Healthcare Association (IPHA)
EU Transparency Register
407098547453-30 First registered on 26 Aug 2022
Goals / Remit
Advance of policies and public support leading to the discovery and adoption of innovative medicines in Ireland and Europe.
Main EU files targeted
The main focus of IPHA activities is targeted at pharmaceutical legislation and policies. The object of our current activities are all the matters contained in the Commission's proposed Pharmaceutical Strategy for the EU, including legislative proposals which may arise from it, including:
- the revision of the Basic Pharmaceutical Regulation
- the revision of the Orphans Medicines Regulation
- the revision of the Medicinal Products for Paediatric use.
The activities have so far involved having meetings and briefings with MEPs and Irish government members and officials who would be involved in Councils of Ministers. We have not yet had meetings with European Commissioners or Commission officials although we may seek that in the coming months.Address
Head Office
7 Clanwilliam Terrace Grand Canal Quay Dublin 2
Dublin D02 CL64
IRELANDEU Office
7 Clanwilliam Terrace Grand Canal Quay Dublin 2
Dublin D02 CL64
IRELANDWebsite
-
People
Total lobbyists declared
3
Employment time Lobbyists 10% 3 Lobbyists (Full time equivalent)
0.3
Lobbyists with EP accreditation
All Lobbyists with EP accreditation over time
1 accreditations were / are live (in bold) for the selected state of 15 Aug 2023
Name Start date End Date Mr Oliver O'CONNOR 07 Jan 2023 06 Jan 2024 Complementary Information
None
Person in charge of EU relations
Data not provided by Register Secretariat due to GDPR
Person with legal responsibility
Data not provided by Register Secretariat due to GDPR
-
Categories
Category
Trade and business associations
-
Networking
Affiliation
www.efpia.eu
www.aefgp.euMember organisations
None declared
-
Financial Data
Interests represented
Promotes their own interests or the collective interests of their members
Closed financial year
Jan 2021 - Dec 2021
Lobbying costs for closed financial year
50,000€ - 99,999€
Major contributions in closed year
None declared
Intermediaries for closed year
None declaredIntermediaries for current year
None declaredClosed year Costs
50,000€ - 99,999€
Other financial info
We estimate direct costs in the 12 months ending 31st December 2021 to have been nil. In the financial year most recently closed, we did not hire any consultant or intermediary to assist us with the relevant work.
For 2021, we have no intermediary. In 2022, we have hired the public affairs consulting firm, Vulcan Consulting (https://vulcanconsulting.eu); The Merrion Buildings, 18-20 Merrion Street Upper, Dublin D02 XH98) in relation to the activities described in Heading 9. We do not fully outsource this activity or our representation to the firm. Financial details for 2022 to follow on in subsequent declarations. -
EU Structures
Groups (European Commission)
none
Groups (European Parliament)
N/A
Communication activities
Public information, conferences (online and in-person), meetings with MEPs in EU Commission and Ireland's Permanent Representative.
Other activities
None declared
- Meetings
Meetings
1 meetings found. Download meetings
The list below only covers meetings held since November 2014 with commissioners, their cabinet members or directors-general at the European Commission; other lobby meetings with lower-level staff may have taken place, but the European Commission doesn't proactively publish information about these meetings. For more information about which commissioner is responsible for which portfolio, check out this link: https://commissioners.ec.europa.eu/index_en All information below comes from European Commission web pages.
-
Date 10 Feb 2023 Location Brussels Subject Discussion of upcoming pharmaceutical package; value of predictability (IP), EU pharmaceutical product approval process, competitiveness, unmet medical needs. Cabinet Cabinet of Commissioner Mairead Mcguinness Portfolio Financial services, financial stability and Capital Markets Union Attending - Patricia Reilly (Cabinet member)
Other Lobbyists
- Meetings